Your session is about to expire
← Back to Search
Paclitaxel + Trastuzumab + Pertuzumab for Inflammatory Breast Cancer
Study Summary
This trial is testing the safety and effectiveness of an investigational drug to see if it works in treating a specific cancer. The drug, pertuzumab, is being studied in combination with paclitaxel and trastuzumab as a preoperative treatment for inflammatory breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have cancer that has spread to my brain.I have trouble breathing even when I'm resting due to lung disease or cancer.I have been diagnosed with inflammatory breast cancer.I am willing to have a biopsy of my affected breast for research.My cancer has not spread to my organs or bones, but may be in many lymph nodes.I have received treatment for breast cancer before.I do not have any unmanaged ongoing illnesses.I've been cancer-free for 5 years, or I've only had cervical cancer in situ, basal, or squamous cell skin cancer.I am allergic to certain cancer drugs like paclitaxel or trastuzumab.I am HIV positive and on combination anti-retroviral therapy.My breast cancer is HER2 positive.My breast cancer diagnosis was confirmed through a biopsy.
- Group 1: Treatment Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this the inaugural analysis of its type?
"Presently, 1826 Doxorubicin trials are being hosted in 82 countries and 3702 cities. The inaugural study for this drug was sponsored by Alfacell back in 1997; it involved 300 patients and concluded with a Phase 3 approval stage. Over the past 24 years, 2743 studies have been completed on Doxorubicin's effects."
How many participants are contributing to this clinical experiment?
"This clinical trial has surpassed its recruitment phase; the initial post was dated August 1st 2013, and it last edited on May 2nd 2022. However, if you are still in search of trials to participate in there currently 2596 studies for breast cancer actively recruiting patients as well 1826 research projects that are seeking participants who will be administered doxorubicin."
Is this research experiment taking on new participants?
"This medical study is no longer recruiting patients. It was first posted on August 1st 2013 and last updated May 2nd 2022. If you are trying to find other trials, there are 2596 studies for breast cancer and 1826 for Doxorubicin currently enrolling participants."
What have studies revealed to be the primary clinical application of Doxorubicin?
"Cyclophosphamide is typically administered in conjunction with Doxorubicin, which has been demonstrated to be beneficial for managing the progression of kaposi's sarcoma aids related, leukemia and locally advanced non-small cell lung cancer."
What progress is hoped to be attained from this trial?
"Over an 18 week period, this trial will evaluate the Percentage of Participants With a Pathologic Complete Response (pCR), as well as Median Overall Survival, Residual Disease Rate by Intrinsic Subtype and Predictive Accuracy Rates between Pre-Treatment and On-Treatment Tumor Biopsy RNA Sequencing Profiles. The pCR is defined as no evidence of invasive carcinoma within both breast tissue and axillary lymph nodes after preoperative treatment; while overall survival measures how long patients live from when they start treatment to death or last known date alive. Furthermore, residual disease rate evaluates cancer proliferation based on intrinsic sub"
Has Doxorubicin been sanctioned by the FDA?
"Our team at Power rated Doxorubicin's safety as a 2 since this is a Phase 2 trial, which suggests that there are some data points affirming its security but none confirming its efficacy."
Can you elucidate on the other research studies that have been conducted using Doxorubicin?
"Doxorubicin was initially explored in 1997 by the scientists at Spectrum Health Hospital - Butterworth Campus. Presently, there are 2743 finished trials and 1826 active studies, with Ann Arbor being a major hub of research."
Share this study with friends
Copy Link
Messenger